No abstract available.
Glomerulonephritis, IGA* ; Immunoglobulin A*

BACKGROUND: Oxidative stress contributes to vascular diseases in patients with diabetes. As the mechanism of development and progression of diabetic vascular complications is poorly understood, this study was aimed to assess the potential role of hyperglycemia-induced oxidative stress and to determine whether the oxidative stress is a major factor in hyperglycemia-induced migration of vascular smooth muscle cells (VSMCs). METHODS: We treated primary cultured rat aortic smooth muscle cells for 72 hours with medium containing 5.5 mM D-glucose (normal glucose), 30 mM D-glucose (high glucose) or 5.5 mM D-glucose plus 24.5 mM mannitol (osmotic control). We measured the migration of VSMCs and superoxide production. Immunoblotting of PKC isozymes using phoshospecific antibodies was performed, and PKC activity was also measured. RESULTS: Migration of VSMCs incubated under high glucose condition were markedly increased compared to normal glucose condition. Treatment with diphenyleneiodonium (DPI, 10 micromol/L) and superoxide dismutase (SOD, 500 U/mL) significantly suppressed high glucose-induced migration of VSMCs. Superoxide production was significantly increased in high glucose condition and was markedly decreased after treatment with DPI and SOD. High glucose also markedly increased activity of PKC-delta isozyme. When VSMCs were treated with rottlerin or transfected with PKC-delta siRNA, nitro blue tetrazolium (NBT) staining and NAD(P)H oxidase activity were significantly attenuated in the high glucose-treated VSMCs. Furthermore, inhibition of PKC-delta markedly decreased VSMC migration by high glucose. CONCLUSION: These results suggest that high glucose-induced VSMC migration is dependent upon activation of PKC-delta, which may responsible for elevated intracellular ROS production in VSMCs, and this is mediated by NAD(P)H oxidase.
Acetophenones ; Animals ; Antibodies ; Benzopyrans ; Diabetic Angiopathies ; Glucose ; Humans ; Immunoblotting ; Isoenzymes ; Mannitol ; Muscle, Smooth, Vascular ; Myocytes, Smooth Muscle ; NADPH Oxidase ; Onium Compounds ; Oxidative Stress ; Oxygen ; Protein Kinase C ; Rats ; RNA, Small Interfering ; Superoxide Dismutase ; Superoxides ; Vascular Diseases

No abstract available.
Hair* ; Hypopigmentation* ; Scalp* ; Ureter*

Cutaneous horn is a nonspecific clinical description and may arise from a variety of benign and malignant lesions. A 46-year-old Korean man presented with a 1-year history of an extensively hyperkeratotic nodule on his left foot. Following an initial diagnosis of dermatofibroma with underlying cutaneous horn by wedge biopsy, the tumor was completely removed by excision with 5 mm margin. When excisional surgery was performed, the size of the dermal tumor mass was found to be 1.3 cm in length on the axis and 0.6 cm in depth on section. On histopathologic examination, the tumor was characterized by spindle-shaped cells arranged in storiform pattern, epidermal hyperplasia, and an overlying compact hyperkeratotic mass. The tumor cells did not express CD34. Cutaneous horn of dermatofibroma may be the product of epidermis-dermal tumor interaction. Although we performed a wide excision for complete removal of the tumor, Mohs micrographic surgery could have been another option.
Animals ; Axis, Cervical Vertebra ; Biopsy ; Diagnosis ; Foot ; Histiocytoma, Benign Fibrous* ; Horns* ; Humans ; Hyperplasia ; Middle Aged ; Mohs Surgery

BACKGROUND: The aim of this study was to evaluate whether continuous infusion of remifentanil during propofol anesthesia could produce opioid-induced hyperalgesia (OIH) and whether an intravenous bolus of fentanyl could control OIH in the management of postoperative pain. METHODS: One hundred fifty-nine women undergoing gynecologic surgery were randomly divided into four groups. Group C: nitrous oxide and propofol infusion (3-4 microg/ml, n = 40), Group F: propofol infusion and intravenous bolus administration of fentanyl (1 microg/kg) after suturing the peritoneum (n = 40), Group R: propofol and remifentanil infusion (2-4 ng/ml, n = 40) and Group RF: propofol, remifentanil infusion and intravenous bolus administration of fentanyl (n = 39). Patient controlled analgesia was started after the operation. The postoperative visual analog scale (VAS) was measured in the recovery room, then at 2 h, 6 h, 12 h, and 24 h after the operation. RESULTS: The VAS scores for Groups R and F in the recovery room were lower than for group C (P < 0.05), but there were no differences 2 h after the operation. The VAS scores for Group RF 6 h and 12 h after the operation were higher than those for group C (P < 0.05). CONCLUSIONS: Our results suggest that low dose (2-4 ng/ml) continuous infusion of remifentanil during propofol anesthesia does not produce marked hyperalgesia. However, an intravenous bolus of fentanyl can aggravate OIH induced by remifentanil.
Analgesia, Patient-Controlled ; Anesthesia ; Female ; Fentanyl ; Gynecologic Surgical Procedures ; Humans ; Hyperalgesia ; Nitrous Oxide ; Pain, Postoperative ; Peritoneum ; Piperidines ; Propofol ; Recovery Room

BACKGROUND: The aim of this study was to evaluate whether continuous infusion of remifentanil during propofol anesthesia could produce opioid-induced hyperalgesia (OIH) and whether an intravenous bolus of fentanyl could control OIH in the management of postoperative pain. METHODS: One hundred fifty-nine women undergoing gynecologic surgery were randomly divided into four groups. Group C: nitrous oxide and propofol infusion (3-4 microg/ml, n = 40), Group F: propofol infusion and intravenous bolus administration of fentanyl (1 microg/kg) after suturing the peritoneum (n = 40), Group R: propofol and remifentanil infusion (2-4 ng/ml, n = 40) and Group RF: propofol, remifentanil infusion and intravenous bolus administration of fentanyl (n = 39). Patient controlled analgesia was started after the operation. The postoperative visual analog scale (VAS) was measured in the recovery room, then at 2 h, 6 h, 12 h, and 24 h after the operation. RESULTS: The VAS scores for Groups R and F in the recovery room were lower than for group C (P < 0.05), but there were no differences 2 h after the operation. The VAS scores for Group RF 6 h and 12 h after the operation were higher than those for group C (P < 0.05). CONCLUSIONS: Our results suggest that low dose (2-4 ng/ml) continuous infusion of remifentanil during propofol anesthesia does not produce marked hyperalgesia. However, an intravenous bolus of fentanyl can aggravate OIH induced by remifentanil.
Analgesia, Patient-Controlled ; Anesthesia ; Female ; Fentanyl ; Gynecologic Surgical Procedures ; Humans ; Hyperalgesia ; Nitrous Oxide ; Pain, Postoperative ; Peritoneum ; Piperidines ; Propofol ; Recovery Room

To investigate the effect of intrathecal fentanyl,36 ASA physieal status 1 or 2 parturients who underwent cesarean section with apinal anesthesis using 0.25% bupivacaine in 5.0% dextroae with 0.25mg morphine were studied. Patients were randomly allocated to receive either saline 0.2ml (group 1, n=17) or fentanyl 10ug(group 2, n=19) in 3.525ml volume mixed with the bupivacaine with morphine. Spinal anesthesia was performed in sitting position using a 25 guage spinal needle. At the completion of injection, patients immediately turned supine with left uterine diaplacement. There was no statistically significant difference in the incidence of the hypotension between groups. The progress of sensory and motor blocks was similar in the two groups. The times from drug injection ta the onset to maximal sensory blockade and complete motor blockade, complete recovery of sensation and motor power were not different between groups. post delivery,the incidence of visceral pain were significantly less in group 2, as 2 of 19 patients(10%) in group 2 compared to 8 of 17 patients(47%) in group 1(p< 0.05). The effective analgesia time was no significant different: 31.7+/-2.5 hour in group 1 compared to 28.6+/-5.6 hour in Group 2. The ineidence of patients not requiring narcotics until discharge was similar in two groups. No patient showed any evidence of respiratory depression. The incidence of other side effects,such as nausea,vomiting and pruritus was not different between groups. No neonate had an Apgar score below 7.
Analgesia ; Anesthesia, Spinal ; Apgar Score ; Bupivacaine* ; Cesarean Section* ; Female ; Fentanyl* ; Humans ; Hypotension ; Incidence ; Infant, Newborn ; Morphine* ; Narcotics ; Needles ; Pregnancy ; Pruritus ; Respiratory Insufficiency ; Sensation ; Visceral Pain

To investigate the effect of intrathecal fentanyl,36 ASA physieal status 1 or 2 parturients who underwent cesarean section with apinal anesthesis using 0.25% bupivacaine in 5.0% dextroae with 0.25mg morphine were studied. Patients were randomly allocated to receive either saline 0.2ml (group 1, n=17) or fentanyl 10ug(group 2, n=19) in 3.525ml volume mixed with the bupivacaine with morphine. Spinal anesthesia was performed in sitting position using a 25 guage spinal needle. At the completion of injection, patients immediately turned supine with left uterine diaplacement. There was no statistically significant difference in the incidence of the hypotension between groups. The progress of sensory and motor blocks was similar in the two groups. The times from drug injection ta the onset to maximal sensory blockade and complete motor blockade, complete recovery of sensation and motor power were not different between groups. post delivery,the incidence of visceral pain were significantly less in group 2, as 2 of 19 patients(10%) in group 2 compared to 8 of 17 patients(47%) in group 1(p< 0.05). The effective analgesia time was no significant different: 31.7+/-2.5 hour in group 1 compared to 28.6+/-5.6 hour in Group 2. The ineidence of patients not requiring narcotics until discharge was similar in two groups. No patient showed any evidence of respiratory depression. The incidence of other side effects,such as nausea,vomiting and pruritus was not different between groups. No neonate had an Apgar score below 7.
Analgesia ; Anesthesia, Spinal ; Apgar Score ; Bupivacaine* ; Cesarean Section* ; Female ; Fentanyl* ; Humans ; Hypotension ; Incidence ; Infant, Newborn ; Morphine* ; Narcotics ; Needles ; Pregnancy ; Pruritus ; Respiratory Insufficiency ; Sensation ; Visceral Pain

To study the differenced of bone mineral density according to the gestational ages and the birth weight and get a reference data for the diagnosis of metabolic bone diseases in the newborn infants, bone mineral densities of the lumbar vertebrae were measured in fifty-three newborn infants bone at Yeungnam University Hospital from March 1, 1995 to February 28, 1997, whose gestational ages were between 28+3 and 41+3 weeks and who had no intrauterine growth retardation, using dual energy X-ray absorptiometry (X-R 26, Norland, USA) within seven days of life. 1. There was no sexual difference in bone mineral density. The bone density increased significantly as gestational age increased from 0.149+/-0.009 g/cm2 at 28-30wks to 0.229+/-0.034 g/cm2 at 39-41wks of gestational age (p<0.05), but there was no significant difference between bone mineral density at 33-34wks and 35-36wks. There was positive linear correlation netween gestational age and bone mineral density (Y=7.5?10-3X-0.082, r=0.7018, p<0.001). 2. The bone mineral density increased significantly as the birth weight increased from 0.158+/-0.020 g/cm2 in 1,000-1,499 g to 0.251+/-0.021 g/cm2 in 3,500-4,000 g of the birth weight (p<0.05), but there was no significant difference between bone mineral densities in 1,000-1,499 g and 1,500-1,999 g of the birth weight. There was positive linear correlation between the birth weight and the bone mineral density (Y=3.9?10-5X+0.093, r=0.7296, p<0.001). There were positive correlations between the bone mineral density and gestational age, and between the bone mineral density and the birth weight. It can be used as a reference data for the further study on the bone mineral metabolism in the newborn infants including preterm babies.
Absorptiometry, Photon ; Birth Weight* ; Bone Density* ; Bone Diseases, Metabolic ; Diagnosis ; Fetal Growth Retardation ; Gestational Age* ; Humans ; Infant, Newborn* ; Lumbar Vertebrae ; Metabolism ; Parturition*

No abstract available.
Infection Control* ; Jeollanam-do*